Skip to content
★ Sign in to follow
RV

Ravi Viswanathan

Shareholder
Epizyme, Inc.Ardelyx, Inc.Elastic N.V.Aveo Pharmaceuticals, Inc.Adaptimmune Therapeutics PLCSurface Oncology, Inc.Mulesoft, IncSynlogic, Inc.
Total declarations
179
Companies
30
▲ Purchases (68 ops.)
€228.5M
▼ Sales (12 ops.)
€107.5M

Latest filing published 10 Oct 2018 for Elastic N.V..

Filing timeline

BuySale
Ravi Viswanathan

Insider track record

Disclosed buys
68
Disclosed sells
12
Signal history

Closed purchases

Market purchases
68

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Ravi Viswanathan: trading record in brief

Ravi Viswanathan discloses dealings in 30 companies, chiefly TESARO, Inc., Aveo Pharmaceuticals, Inc. and Epizyme, Inc. Over a trading history stretching from 21 November 2011 to 10 October 2018, the count stands at 179 filings.

Market trades split into 68 purchases (€228.5M) and 12 sales (€107.5M). The net balance comes to €121.0M on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 5 share grants. Since January 2018: 38 purchases and 1 sale on the market.

The median purchase comes to €1.3M. Clusters matter here: 52 out of 52 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 10 October 2018: a transaction, in Elastic N.V. The clock since the last published purchase (10 September 2018) now reads 2,981 days. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Ravi Viswanathan

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations134 total
  • ●
    10% OwnerExecutivesElastic N.V.
    0SEC
    4,155,995 sharesOrdinary SharesSEC:0001209191-18-054723:0
  • ●
    10% OwnerExecutivesElastic N.V.
    0SEC
    1,528,117 sharesOrdinary SharesSEC:0001209191-18-054723:1
  • ▲
    10% OwnerExecutivesAdaptimmune Therapeutics PLC
    5M USD30SEC
    3,000,000 shares@ US$1.6712.8% of flowOrdinary Shares with a nominal value of 0.001 GBP per shareSEC:0001209191-18-050293:0
    Canonical exit: 6 Dec 2018 (T+90)
  • ▲
    10% OwnerExecutivesAdaptimmune Therapeutics PLC
    20M USD34SEC
    12,000,000 shares@ US$1.6751.2% of flowOrdinary Shares with a nominal value of 0.001 GBP per shareSEC:0001209191-18-050293:1
    Canonical exit: 6 Dec 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.

    Same trade as the filing by Growth Equity Opportunities IV, LLC, counted once

    1M USD32SEC
    663,716 shares@ US$2.2629.8% of flowCommon StockSEC:0001209191-18-047972:0
    Canonical exit: 19 Nov 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.
    390,000 USD30SEC
    200,000 shares@ US$1.957.7% of flowCommon StockSEC:0001209191-18-043489:0
    Canonical exit: 16 Oct 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.
    101,200 USD29SEC
    50,600 shares@ US$2.002.0% of flowCommon StockSEC:0001209191-18-043489:1
    Canonical exit: 17 Oct 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.
    392,973 USD30SEC
    187,130 shares@ US$2.107.8% of flowCommon StockSEC:0001209191-18-039969:1
    Canonical exit: 26 Sept 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.

    Same trade as the filing by Growth Equity Opportunities IV, LLC, counted once

    11,384 USD29SEC
    5,295 shares@ US$2.150.2% of flowCommon StockSEC:0001209191-18-039969:0
    Canonical exit: 25 Sept 2018 (T+90)
  • ◆
    10% OwnerExecutivesArdelyx, Inc.
    2M USD6SEC
    416,666 shares@ US$4.007.3% of flowCommon StockSEC:0001209191-18-034182:0
  • ◆
    10% OwnerExecutivesArdelyx, Inc.
    2M USD6SEC
    416,667 shares@ US$4.007.3% of flowCommon StockSEC:0001209191-18-034182:1
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.

    Same trade as the filing by Growth Equity Opportunities IV, LLC, counted once

    591 USD29SEC
    275 shares@ US$2.150.0% of flowCommon StockSEC:0001209191-18-034194:0
    Canonical exit: 28 Aug 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.
    392,301 USD29SEC
    184,179 shares@ US$2.134.7% of flowCommon StockSEC:0001209191-18-031990:0
    Canonical exit: 15 Aug 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.
    43,014 USD29SEC
    20,100 shares@ US$2.140.5% of flowCommon StockSEC:0001209191-18-031990:1
    Canonical exit: 16 Aug 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.
    68,908 USD29SEC
    32,200 shares@ US$2.140.8% of flowCommon StockSEC:0001209191-18-031990:2
    Canonical exit: 19 Aug 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.
    150,959 USD29SEC
    70,873 shares@ US$2.131.8% of flowCommon StockSEC:0001209191-18-029305:0
    Canonical exit: 6 Aug 2018 (T+90)
  • ●
    10% OwnerExecutivesMulesoft, Inc
    0SEC
    12,679,970 sharesClass A Common StockSEC:0001209191-18-028795:0
  • ●
    10% OwnerExecutivesMulesoft, Inc
    0SEC
    12,679,970 sharesClass A Common StockSEC:0001209191-18-028795:1
  • ●
    10% OwnerExecutivesMulesoft, Inc
    0SEC
    2,576,939 sharesClass A Common StockSEC:0001209191-18-028795:2
  • ●
    10% OwnerExecutivesMulesoft, Inc
    0SEC
    2,576,939 sharesClass A Common StockSEC:0001209191-18-028795:3
  • ●
    10% OwnerExecutivesMulesoft, Inc
    0SEC
    858,978 sharesClass A Common StockSEC:0001209191-18-028795:4
  • ●
    10% OwnerExecutivesMulesoft, Inc
    0SEC
    858,978 sharesClass A Common StockSEC:0001209191-18-028795:5
  • ●
    10% OwnerExecutivesSurface Oncology, Inc.
    0SEC
    3,179,544 sharesCommon StockSEC:0001209191-18-025852:0
  • ▲
    10% OwnerExecutivesSurface Oncology, Inc.

    Same trade as the filing by Scott D. Sandell, counted once

    2M USD31SEC
    133,333 shares@ US$15.00100.0% of flowCommon StockSEC:0001209191-18-025852:1
    Canonical exit: 22 Jul 2018 (T+90)
  • ▲
    10% OwnerExecutivesAveo Pharmaceuticals, Inc.
    2M USD25SEC
    685,676 shares@ US$2.2417.6% of flowCommon StockSEC:0001209191-18-024543:0
    Canonical exit: 5 Jul 2018 (T+90)

25 of 134 declarations